DrugPatentWatch Database Preview
INBRIJA Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Inbrija, and when can generic versions of Inbrija launch?
Inbrija is a drug marketed by Acorda and is included in one NDA. There are eighteen patents protecting this drug.
This drug has one hundred and forty-eight patent family members in twenty-six countries.
The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.
US ANDA Litigation and Generic Entry Outlook for Inbrija
Indicators of Generic Entry
Summary for INBRIJA
| International Patents: | 148 |
| US Patents: | 18 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 113 |
| Patent Applications: | 4,145 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for INBRIJA |
| DailyMed Link: | INBRIJA at DailyMed |
Pharmacology for INBRIJA
| Drug Class | Aromatic Amino Acid |
US Patents and Regulatory Information for INBRIJA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INBRIJA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | Start Trial | Start Trial |
| Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INBRIJA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 2630954 | Start Trial |
| Hong Kong | 1061658 | Start Trial |
| Australia | 9112201 | Start Trial |
| Japan | 2015536989 | Start Trial |
| Japan | 2004509141 | Start Trial |
| Cyprus | 1108214 | Start Trial |
| Australia | 2013342247 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for INBRIJA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1613296 | CR 2015 00042 | Denmark | Start Trial | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
| 1613296 | 92782 | Luxembourg | Start Trial | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
